Disc Medicine priced an upsized public share offering with expected gross proceeds of $450 million, according to its 20 October 2026 announcement. The biotechnology company offered 6 million common shares at $75 each. This is a follow-on financing by an already listed issuer, not a new IPO, and the announced amount is before underwriting discounts, commissions and other expenses.
The release expected the transaction to close on 22 October, subject to customary conditions. The current source check did not establish that closing occurred. A scheduled date passing is not itself evidence of completed fundraising.
The confirmed offer terms
| Field | Officially disclosed position | Official evidence |
|---|---|---|
| Issuer and stage | Disc Medicine, Nasdaq: IRON; priced follow-on offering | Issuer source |
| Common shares offered | 6,000,000 | Issuer source |
| Public offering price | $75.00 per share | Issuer source |
| Expected gross proceeds | $450 million before expenses; excludes option exercise | Issuer source |
| Underwriters’ option | 30 days to buy up to 900,000 additional shares | Issuer source |
| Closing timetable | Expected 22 October 2026, subject to customary conditions | Issuer source |
| IPO status | Not an IPO; common shares already listed | Issuer source |
The gross-size calculation is 6,000,000 shares multiplied by $75, which equals $450 million. Gross proceeds are not the same as net proceeds: underwriting charges and other offering costs reduce the funds retained by the issuer. The pricing announcement does not give a final net-proceeds figure, so this report does not invent one.
Where the money is intended to go
Disc said it intended to combine the net proceeds with existing cash and marketable securities to finance research and clinical development of current or additional candidates. It also identified potential commercialization of bitopertin for erythropoietic protoporphyria and X-linked protoporphyria, other pre-commercialization work, and working capital and general corporate purposes.
Those are intended uses, not evidence that the money has already been spent or that a product has received regulatory approval. A financing announcement does not establish clinical success, marketing authorization, future revenue or a return to shareholders.
Why this is not an IPO
An IPO introduces shares to the public market for the first time. Disc was already trading under IRON and said this offering was made under an existing automatic shelf registration on Form S-3. The company itself is selling these shares; the proceeds should not be described as a cash payment to existing shareholders.
By contrast, CapKet’s City Therapeutics IPO report concerns an initial offering. Price, size and offer stage need to be read separately for each issuer. This report does not provide an application recommendation or assume an underwriting option was exercised.
Official sources and verification
Official announcement (observed 2026-10-22T19:45:41.870Z); Issuer results/news index (observed 2026-10-22T19:45:41.783Z). An issuer index confirms publication availability, not independent corroboration of the figures. Material amounts and qualifications were checked in the linked primary documents. This is AI-assisted primary-document review, not independent human editorial approval. Information only, not investment advice.
Recorded source observation: . This is a source-check timestamp, not a market quote or a new article update.